"There is a need to reassess the assumption that e-cigarette use provides substantial harm reduction across all cigarette-caused diseases, particularly accounting for dual use," warns a comprehensive meta-analysis.
"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.
In a registry-based study of 79,550 patients, tenecteplase showed comparable short-term safety and effectiveness to alteplase for acute ischemic stroke, with no significant differences in functional outcomes or hemorrhagic events.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.